Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ784118B2 - 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives - Google Patents
[go: Go Back, main page]

NZ784118B2 - 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives - Google Patents

3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives Download PDF

Info

Publication number
NZ784118B2
NZ784118B2 NZ784118A NZ78411817A NZ784118B2 NZ 784118 B2 NZ784118 B2 NZ 784118B2 NZ 784118 A NZ784118 A NZ 784118A NZ 78411817 A NZ78411817 A NZ 78411817A NZ 784118 B2 NZ784118 B2 NZ 784118B2
Authority
NZ
New Zealand
Prior art keywords
unsubstituted
unsaturated
saturated
alkyl
polysubstituted
Prior art date
Application number
NZ784118A
Other versions
NZ784118A (en
Inventor
Ruth Jostock
Achim Kless
Thomas Koch
Rene Michael Koenigs
Ingo Konetzki
Sven Kuhnert
Klaus Linz
Paul Ratcliffe
Wolfgang Schroder
Anita Wegert
Original Assignee
Grünenthal GmbH
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of NZ784118A publication Critical patent/NZ784118A/en
Publication of NZ784118B2 publication Critical patent/NZ784118B2/en

Links

Abstract

The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives of formula (I), their preparation and their use in medicine, particularly in the treatment of pain.

Claims (1)

1.patent claims [0014a] In one embodiment, there is provided use of a compound according to general formula (I) 13 16 R 14 R 17 20 wherein R and R independently of one another mean -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -OH, -OCH , -CN and -CO CH ; 3 2 3 a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -OH, -OCH , -CN and -CO CH ; wherein 3 2 3 said 3membered cycloalkyl moiety is optionally connected through -C -C -alkylene- , linear or branched, saturated or unsaturated, unsubstituted; or a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -OH, -OCH , -CN and -CO CH ; wherein 3 2 3 said 3membered heterocycloalkyl moiety is optionally connected through -C -C - alkylene-, linear or branched, saturated or unsaturated, unsubstituted; R and R together with the nitrogen atom to which they are attached form a ring and mean -(CH ) -; -(CH ) -O-(CH ) -; or -(CH ) -NR -(CH ) -, wherein R means -H or 2 3-6 2 2 2 2 2 2 2 2 -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br and -I; R means -C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3membered cycloalkyl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3membered heterocycloalkyl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 6membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6- 14-membered aryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 5membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5membered heteroaryl moiety is optionally connected through -C -C -alkylene- , linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; R means -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said -C -C -alkyl is optionally connected through -C(=O)-, - C(=O)O-, or -S(=O) -; a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3membered cycloalkyl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3membered cycloalkyl moiety is optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O-CH -, or -S(=O) -; a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3membered heterocycloalkyl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3membered heterocycloalkyl moiety is optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O- CH2-, or -S(=O)2-; a 6membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6- 14-membered aryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 6membered aryl moiety is optionally connected through -C(=O)-, -C(=O)O-, - C(=O)O-CH -, or -S(=O) -; or a 5membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5membered heteroaryl moiety is optionally connected through -C -C -alkylene- , linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 5membered heteroaryl moiety is optionally connected through -C(=O)- , -C(=O)O-, -C(=O)O-CH -, or -S(=O) -; R means a 6membered aryl moiety, unsubstituted, mono- or polysubstituted; or a 5membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; 11 12 13 14 15 16 17 18 19 20 R , R , R , R , R , R , R , R , R , and R independently of one another mean - H, -F, -Cl, -Br, -I, -OH, or -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein "mono- or polysubstituted" means that one or more hydrogen atoms are replaced by a substituent independently of one another selected from the group consisting of -F, - 21 21 21 21 22 Cl, -Br, -I, -CN, -R , -C(=O)R , -C(=O)OR , -C(=O)NR R , -C(=O)NH-(CH CH - 21 21 O) -CH , -O-(CH CH -O) -H, -O-(CH CH -O) -CH , =O, -OR , -OC(=O)R , - 1-30 3 2 2 1-30 2 2 1-30 3 21 21 22 21 22 21 22 21 OC(=O)OR , -OC(=O)NR R , -NO , -NR R , -NR -(CH ) -C(=O)R , -NR - 2 2 1-6 22 23 21 22 21 22 21 (CH ) -C(=O)OR , -NR -(CH ) -C(=O)NR R , -NR C(=O)R , -NR C(=O)- 2 1-6 2 1-6 22 23 21 22 21 22 21 21 21 OR , -NR C(=O)NR R , -NR S(=O)2R , -SR , -S(=O)R , -S(=O)2R , - 21 21 22 S(=O) OR , and -S(=O) NR R ; wherein 21 22 23 R , R and R independently of one another mean -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH2, -CO2H, -C(=O)O-C1-C6-alkyl, - C(=O)NH , -C(=O)NHC -C -alkyl, -C(=O)N(C -C -alkyl) , -O-C -C -alkyl and - 2 1 6 1 6 2 1 6 S(=O) -C -C -alkyl; 2 1 6 a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3membered cycloalkyl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH , -C -C -alkyl and -O-C - 2 1 6 1 C -alkyl; a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3membered heterocycloalkyl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH , -C -C -alkyl and -O-C -C -alkyl; 2 1 6 1 6 a 6membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6- 14-membered aryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH , -C -C -alkyl and -O-C -C -alkyl; 2 1 6 1 6 a 5membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5membered heteroaryl moiety is optionally connected through -C -C -alkylene- , linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH , -C -C -alkyl and -O-C -C -alkyl; 2 1 6 1 6 21 22 21 22 21 22 21 22 23 or R and R within -C(=O)NR R , -OC(=O)NR R , -NR R , -NR -(CH2)1 21 22 23 21 22 21 22 C(=O)NR R , -NR C(=O)NR R , or -S(=O) NR R together with the nitrogen atom to which they are attached form a ring and mean -(CH ) -; -(CH ) -O-(CH ) -; - 2 3-6 2 2 2 2 (CH ) -S(=O) -(CH ) - or -(CH ) -NR -(CH ) -, wherein R means -H, -C -C -alkyl, - 2 2 2 2 2 2 2 2 2 1 6 C(=O)-C -C -alkyl, or -S(=O) -C -C -alkyl, wherein said C -C -alkyl is linear or 1 6 2 1 6 1 6 branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -OH, -CO2H, -C(=O)O-C1-C6-alkyl and -C(=O)NH2; and wherein said ring is unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, =O, -OH, -NH , -C - C -alkyl and -O-C -C -alkyl; 6 1 6 or a physiologically acceptable salt thereof; for the manufacture of a medicament for treating pain.
NZ784118A 2017-01-13 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives NZ784118B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16151012 2016-01-13
NZ745185A NZ745185B2 (en) 2017-01-13 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Publications (2)

Publication Number Publication Date
NZ784118A NZ784118A (en) 2024-03-22
NZ784118B2 true NZ784118B2 (en) 2024-06-25

Family

ID=

Similar Documents

Publication Publication Date Title
ES2620316T3 (en) Cycloalkenopyrazoles substituted as BUB1 inhibitors for cancer treatment
ES2974494T3 (en) Pyridazinone-Fused Tricyclic Compounds Useful for Treating Orthomyxovirus Infections
ES2381057T3 (en) Griseofulvin analogues for cancer treatment by inhibiting centrosomal aggregation
ES2908225T3 (en) Flavaglin derivatives
JP2018522867A5 (en)
EA020885B1 (en) Protein kinase inhibitors and use thereof
TW200815456A (en) Artemisinin derivative dimers, their preparation and their therapeutic application
KR20210126676A (en) Hydroxypyridoxazepine as an Nrf2 activator
CN107382966B (en) A kind of longinamide-ligustrazine hybrid compound, preparation method and medicinal use
JP2007515419A5 (en)
KR101143735B1 (en) Hemiasterlin derivatives and uses thereof
ES2911183T3 (en) Compound for selectively inhibiting kinases and use thereof
BR112020015747A2 (en) SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES
JP2024033009A (en) 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7H-pyrrolo[1',2':4 as an inhibitor of orthomyxovirus replication for treating influenza ,5] pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds
WO2012166658A1 (en) Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
BRPI0509912B1 (en) compounds, process for preparing same, pharmaceutical composition, and use of a compound
AU2007205208B2 (en) Derivatives of sulindac, use thereof and preparation thereof
PT1854800E (en) Antitumoral derivatives of ecteinascidin et-743
JP2012505921A (en) Compositions and methods for treating or preventing hypoxic or ischemic injury
NZ784118B2 (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
NZ784118A (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
WO2020247679A1 (en) Wdr5 inhibitors and modulators
JP6045083B2 (en) Diazonamide analog
EP3094622A1 (en) Water soluble 4-azapodophyllotoxin analogs
Crooks et al. Use of parthenolide derivatives as antileukemic and cytotoxic agents